Biotech Values

[DewDiligence]

Survey of enthusiasm for GLP-1 drugs by prospective users:

https://www.nytimes.com/2023/08/04/health/weight-loss-drugs-obesity-wegovy-ozempic.html

A national survey released on Friday by KFF, a nonprofit organization focused on health policy, has found that Americans long for safe and effective drugs for weight loss. But the more they learn about new drugs like Wegovy that are transforming obesity treatment, the more their enthusiasm fades.

The survey found that 59 percent of people who were trying to lose weight said they were interested in taking a safe and effective drug. But only 23 percent remained interested when asked if they would take such a drug if it had to be injected. And just 16 percent were still interested if their insurance would not pay for the drug. The list price of the drugs is about $1,300 a month.

When they heard they would regain their lost weight it they stopped taking the drug, interest declined to 14 percent.

…The survey was conducted in July online and by telephone with a representative sample of 1,327 U.S. adults.

This questionnaire did not even mention the loss of lean muscle mass, the potential cardiovascular risks, the boxed-warning for thyroid cancer, and the severity of the GI issues for some patients (#msg-172517529).